InMed Pharmaceuticals Inc.
INM
$2.96
$0.24378.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -10.36% | 40.22% | -44.48% | 13.42% | 163.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.36% | 40.22% | -44.48% | 13.42% | 163.98% |
| Cost of Revenue | -28.96% | -12.42% | 10.30% | 4.96% | 170.56% |
| Gross Profit | 42.21% | 2,227.36% | -70.32% | 50.39% | 147.03% |
| SG&A Expenses | 13.90% | 9.49% | -13.87% | -2.73% | -6.89% |
| Depreciation & Amortization | -3.62% | -0.36% | 2.43% | 8.09% | 12.65% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.67% | -14.39% | 16.44% | -6.73% | 8.92% |
| Operating Income | -29.42% | 33.15% | -289.11% | 16.42% | 23.69% |
| Income Before Tax | -74.20% | 33.86% | -473.56% | 13.70% | 29.55% |
| Income Tax Expenses | -- | -- | 294.44% | -- | -- |
| Earnings from Continuing Operations | -74.20% | 33.86% | -472.61% | 13.76% | 29.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.20% | 33.86% | -472.61% | 13.76% | 29.65% |
| EBIT | -29.42% | 33.15% | -289.11% | 16.42% | 23.69% |
| EBITDA | -30.52% | 33.85% | -322.26% | 17.02% | 24.51% |
| EPS Basic | 1.71% | 82.25% | -98.36% | 70.14% | 79.70% |
| Normalized Basic EPS | 1.71% | 82.25% | -98.69% | 70.12% | 79.67% |
| EPS Diluted | 1.71% | 82.25% | -98.36% | 70.14% | 79.70% |
| Normalized Diluted EPS | 1.71% | 82.25% | -98.69% | 70.12% | 79.67% |
| Average Basic Shares Outstanding | 77.20% | 272.66% | 188.57% | 188.82% | 246.70% |
| Average Diluted Shares Outstanding | 77.20% | 272.66% | 188.57% | 188.82% | 246.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |